There are 2789 resources available
1169TiP - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: A phase II clinical study (ALTER-L043)
Presenter: Changli Wang
Session: ePoster Display
1173P - Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC
Presenter: Waleed Kian
Session: ePoster Display
1174P - Preliminary prediction of EGFR-mutant non-small cell lung cancer outcome using radiomic signature
Presenter: Jose Minatta
Session: ePoster Display
Resources:
Abstract
1175P - Predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated on the Pacific regimen
Presenter: Robert Gao
Session: ePoster Display
1176P - Neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in patients with potentially resectable NSCLC: An open-label, single-arm, phase II trial
Presenter: Xinsheng Zhu
Session: ePoster Display
1177P - Real-world treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Middle East and Africa (MEA)-KINDLE study
Presenter: Abdul Rahman Jazieh
Session: ePoster Display
1178P - Senescence signature affects overall survival in non-small cell lung cancer
Presenter: Andreas Domen
Session: ePoster Display
1179P - The effect of neoadjuvant chemotherapy / chemoradiotherapy on tumor tissue PD-L1 and VISTA expression levels in non-small cell lung cancers (NSCLC)
Presenter: Orhun Akdogan
Session: ePoster Display
1180P - Anlotinib combined with radiotherapy in locally advanced non-small cell lung cancer (LANSCLC): A prospective, single-arm, phase II study
Presenter: Peng Ning
Session: ePoster Display
1181P - The impact of dosimetric parameters on pneumonitis in patients with stage III non-small cell lung cancer during maintenance treatment with durvalumab after chemoradiotherapy
Presenter: Martina Vrankar
Session: ePoster Display